Abstract:Human parainfluenza virus type 3 (hPIV-3) is a major respiratory tract pathogen that affects infants and young children. The hPIV-3 hemagglutinin-neuraminidase (HN) protein is a multifunctional protein mediating hemadsorption (HAD), neuraminidase (NA), and fusion promotion activities, each of which affects the ability of HN to promote viral fusion and entry. The hPIV-3 HN protein contains four potential sites (N308, N351, N485 and N523) for N-linked glycosylation. Electrophoretic mobility analysis of mutated HN proteins indicated that N308, N351 and N523 sites, but not the N485 site in HN protein, were targeted for the addition of glycans in BHK-21 cells. These functional glycosylation sites were systematically eliminated in various combinations from HN to form a panel of mutants in which the roles of individual carbohydrate chains and groups of carbohydrate chains could be analyzed. Removal of individual or multiple N-glycans on the hPIV-3 HN protein had no effects on transport to the cell surface, expression and NA activity. Single glycosylation site mutants (G1, G2 and G4) not only impaired fusion promotion activity but also reduced HAD activity of HN protein, which was even more obvious for all three double mutants (G12, G14 and G24) and the triple mutant (G124). In addition, every mutant protein retained F-interactive capability that was equal to the wild-type protein capability. Interestingly, the F protein that could be co-immunoprecipitated with the G12 mutated protein or immunoprecipitated with anti-F antibody was not efficiently cleaved. For G14, G24 and G124, little cleaved F protein was detected in co-immuoprecipitation F protein assay and its total amounts where in the cell lysates. The mechanism underlying hPIV-3 HN and F protein remained associated before and after receptor engagement and the strength of the HN-receptor interaction modulated the activation of F the protein which could determine the extent of fusion. Finally, we demonstrated that single or multiple N-glycosylation site mutations inhibited fusion at the earliest stages. Taken together, these results indicated that N-glycosylation of hPIV-3 HN is critical to its receptor recognition activity, cleavage of the F protein, and fusion promotion activity, but had no influence on its interaction with the homologous F protein and NA activity.

New antiviral approaches for human parainfluenza: Inhibiting the haemagglutinin-neuraminidase

A Dual Drug Regimen Synergistically Blocks Human Parainfluenza Virus Infection

Role of N-linked Glycosylation of the Human Parainfluenza Virus Type 3 Hemagglutinin-Neuraminidase Protein.

Antiviral strategies against human metapneumovirus: Targeting the fusion protein

Advanced in vitro and ex vivo models provide a suitable platform for the evaluation of antiviral small molecules against human parainfluenza virus 3

Progress in the development of human parainfluenza virus vaccines

Recent advances in neuraminidase inhibitor development as anti-influenza drugs.

Functional and structural basis of human parainfluenza virus type 3 neutralization with human monoclonal antibodies

Antiviral strategies against influenza virus: towards new therapeutic approaches

Potential targets and their relevant inhibitors in anti-influenza fields.

Advances in Anti-Influenza Drugs: Neuraminidase Inhibitors

Functional Analysis of Amino Acids at Stalk/head Interface of Human Parainfluenza Virus Type 3 Hemagglutinin-Neuraminidase Protein in the Membrane Fusion Process

Influenza Viruses: Harnessing the Crucial Role of the M2 Ion-Channel and Neuraminidase toward Inhibitor Design

Design, Synthesis, and Biological Evaluation of Novel Penindolone Derivatives As Potential Inhibitors of Hemagglutinin-Mediated Membrane Fusion.

Recent Advances in Novel Antiviral Therapies against Human Adenovirus

Current and novel antiviral strategies for influenza infection

Emerging antiviral therapies and drugs for the treatment of influenza

Influenza A Virus Entry Inhibitors Targeting the Hemagglutinin

Human parainfluenza virus 3 vaccine candidates attenuated by codon-pair deoptimization are immunogenic and protective in hamsters

Progress Of Small Molecular Inhibitors In The Development Of Anti-Influenza Virus Agents

A robust mouse model of HPIV-3 infection and efficacy of GS-441524 against virus-induced lung pathology